- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02542033
Glycemic Response to Low Sugar Apple Juice
Double-blind, Randomized, Controlled, Cross-over Trial on Glycemic Response to Low Sugar Apple Juice
Primary objective of this study is to investigate the effect of sugar reduction (starting from glucose and sucrose, respectively) on postprandial glycemic response to apple juice by comparing the reference food item apple juice (control) with the test product (apple juice with low sugar content) in male humans with impaired fasting glucose (IFG) (5.6-6.9mmol/l resp. 100-125mg/dL) (Kerner and Brückel, 2012 (DDG recommendation)) Secondary objective of this study is to investigate the effect of sugar reduction on postprandial insulinemic response.
Exploratory objectives are to investigate further characteristics of postprandial glucose and insulin response and insulin sensitivity, gastrointestinal side effects and safety aspects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
Investigating the effect of sugar reduction in apple juice on glycemic and insulin response to ingestion of this drink.
Subjects/Methods:
In a double-blind randomized placebo-controlled clinical trial with cross-over design 30 male adults with impaired fasting glucose (IFG) received an oral drink of 500mL: 1. Verum: Apple juice, treated (low sugar content); 2. Control: Untreated apple juice (normal sugar content). Capillary blood glucose and venous plasma insulin were measured twice at baseline and then at times 0 (start of drink), 15, 30, 45, 60, 90 and 120 min.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24118
- Clinical Research Center (CRC) Kiel GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males aged ≥ 18y
- diagnosed impaired fasting glucose (IFG)
- Written informed consent
Exclusion Criteria:
- Subjects currently enrolled in another clinical study
- Subjects having finished another clinical study within the last 4 weeks before inclusion
- Hypersensitivity, allergy or idiosyncratic reaction to apple, apple juice or other apple containing food
- Acute or chronic infections
- Renal insufficiency
- Gastrointestinal illness
- History of gastrointestinal surgery
- Known fructose intolerance
- Overt Diabetes mellitus
- Endocrine disorders
- Any disease or condition which might compromise significantly the hematopoietic, renal, endocrine, pulmonary, hepatic, cardiovascular, immunological, central nervous, dermatological or any other body System with the exception of the conditions defined by the inclusion criteria
- History of hepatitis B and C
- History of HIV infection
- History of coagulation disorders or pharmaceutical anti-coagulation (with the exception of acetylsalicylic acid)
- Regular medical treatment including OTC, which may have impact on the study aims (e.g. antidiabetic drugs, laxatives etc.)
- Major cognitive or psychiatric disorders
- Subjects who are scheduled to undergo hospitalization during the study period
- Eating disorders (e.g. anorexia, bulimia) or special diets (e.g. vegan, vegetarian)
- Present drug abuse or alcoholism
- Legal incapacity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: verum
500mL treated apple juice with low sugar content given on one experimental day
|
Each study participant consumed 500 mL test juice at the morning of the interventional day.
The 500 mL bottle content had to be ingested within 5 minutes.
an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product.
From all samples plasma insulin was measured.
From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined.
Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
|
Placebo Comparator: control
500mL un-treated apple juice with normal sugar content given on one experimental day
|
Each study participant consumed 500 mL test juice at the morning of the interventional day.
The 500 mL bottle content had to be ingested within 5 minutes.
an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product.
From all samples plasma insulin was measured.
From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined.
Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
incremental area under the postprandial glucose curve
Time Frame: 120 min postprandially
|
120 min postprandially
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
incremental area under the postprandial insulin curve
Time Frame: 120 min postprandially
|
120 min postprandially
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HB-RCT1-2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impaired Fasting Glucose
-
GlaxoSmithKlineCompletedImpaired Fasting GlucoseIndia
-
Chinese University of Hong KongUnknownDiabetes | Glucose Intolerance | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)China
-
Yonsei UniversityCompletedImpaired Glucose Tolerance | Impaired Fasting Glucose | NormalKorea, Republic of
-
US Department of Veterans AffairsCompletedImpaired Glucose Tolerance | Impaired Fasting Glucose | Vitamin D InsufficiencyUnited States
-
The University of Hong KongChinese University of Hong KongCompletedProgression From Impaired Fasting Glucose to Diabetes MellitusHong Kong
-
Atheline Major-PedersenBayer; NovartisCompletedInsulin Resistance | Impaired Fasting GlucoseDenmark
-
Procter and GambleDuke UniversityCompletedImpaired Fasting GlucoseUnited States
-
Wroclaw Medical UniversityCompletedPreDiabetes | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)Poland
-
Yuhan CorporationCompletedHypertension | Impaired Fasting Glucose | ASCVDKorea, Republic of
-
University of VermontCompletedImpaired Glucose Tolerance | Pre-diabetes | Impaired Fasting GlucoseUnited States
Clinical Trials on treated apple juice with low sugar content
-
Clinical Nutrition Research Center, Illinois Institute...Completed
-
University Health Network, TorontoCompleted
-
VU University of AmsterdamDutch Heart Foundation; ZonMw: The Netherlands Organisation for Health Research... and other collaboratorsCompleted
-
Tufts UniversityOcean Spray, Inc.Completed
-
Fundación Pública Andaluza para la Investigación...Completed
-
University of BolognaEuropean CommissionUnknown
-
Société des Produits Nestlé (SPN)Active, not recruiting
-
University of HohenheimCompleted
-
Hasselt UniversityHochschule Geisenheim UniversityUnknown